Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
April 8, 2002
- Sankyo Transfers Development of Glaucoma Drug to Santen
April 8, 2002
- Elimination of Prescription Period Limitation Should Help Bungyo : Expert
April 8, 2002
- Nippon Shinyaku to Market HIGA Mice via Japan SLC
April 8, 2002
- Final Draft GL for Acute Pancreatitis Presented by JSAEM
April 8, 2002
- Otsuka, Otsuka Pharm Factory, Snow Brand Milk Create JV for Clinical Nutrition
April 8, 2002
- Korosho to Construct Critical Path-Sharing System
April 8, 2002
- Major Maker's New Invoice Prices Are More Acceptable than Before: Suzuken
April 8, 2002
- Doctors' Participation in Clinical Trial Training Disappointing
April 8, 2002
- BUSINESS NEWS IN BRIEF
April 8, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 8, 2002
- WEBSITE NEWS
April 8, 2002
- Novartis Kao to Be Dissolved
April 8, 2002
- EFPIA Japan to Strengthen European Makers' Presence
April 8, 2002
- Pola Cosmetics Transfers Food Division to Asahi Beer Pharm
April 8, 2002
- Committee Members Criticize Korosho's Healthcare Reform Bill
April 8, 2002
- Pharmarise to Develop Private Brand Supplements
April 8, 2002
- Monkasho to Create WG on Duality of Interest
April 8, 2002
- WSMI Congress to Be Held in Tokyo in November
April 8, 2002
- NEDO Selects Two Medical Device Projects for Funding
April 8, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…